{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:51:04Z","timestamp":1790941864201,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government","award":["2022M3A9J1072296"],"award-info":[{"award-number":["2022M3A9J1072296"]}]},{"name":"Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government","award":["2022M3A9J1072296"],"award-info":[{"award-number":["2022M3A9J1072296"]}]},{"name":"Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government","award":["2022M3A9J1072296"],"award-info":[{"award-number":["2022M3A9J1072296"]}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"publisher","award":["2710008772"],"award-info":[{"award-number":["2710008772"]}],"id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07661-8","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:06:26Z","timestamp":1751396786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of a novel multivalent mRNA vaccine against SARS-CoV-2 in experimental animals"],"prefix":"10.1038","volume":"15","author":[{"given":"Seung Eui","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Seong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Seok","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Ghil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong In","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Jun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Bae","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong-Cheol","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Sun","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Bum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Hyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"7661_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis, D., Jacquinet, E., Rogers, M. A. & Amiji, M. M. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat. Rev. Drug. Discov. 23, 281\u2013300 (2024).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"7661_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","volume":"28","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. The landscape of mRNA nanomedicine. Nat. Med. 28, 2273\u20132287 (2022).","journal-title":"Nat. Med."},{"key":"7661_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/08971900211009650","volume":"35","author":"SP Teo","year":"2021","unstructured":"Teo, S. P. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J. Pharm. Pract. 35, 947\u2013951 (2021).","journal-title":"J. Pharm. Pract."},{"key":"7661_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"7661_CR5","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833\u20131840 (2008).","journal-title":"Mol. Ther."},{"key":"7661_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6. mRNA-based therapeutics\u2014developing a new class of drugs. Nat. Rev. Drug. Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"7661_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug. Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"7661_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","volume":"387","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. A bivalent Omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279\u20131291 (2022).","journal-title":"N. Engl. J. Med."},{"key":"7661_CR9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1101\/gad.5.11.2108","volume":"5","author":"D Gallie","year":"1991","unstructured":"Gallie, D. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Gene. Dev. 5, 2108\u20132116 (1991).","journal-title":"Gene. Dev."},{"key":"7661_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood.V66.5.1149.1149","volume":"66","author":"J Ross","year":"1985","unstructured":"Ross, J. & Sullivan, T. D. Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes. Blood 66, 1149\u20131154 (1985).","journal-title":"Blood"},{"key":"7661_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"7661_CR12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"94","key":"7661_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal. Transduct. Target. Ther. 7(94), 94 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"7661_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/d41573-021-00176-7","volume":"20","author":"E Dolgin","year":"2021","unstructured":"Dolgin, E. mRNA flu shots move into trials. Nat. Rev. Drug. Discov. 20, 801\u2013803 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"7661_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","volume":"23","author":"B Essink","year":"2023","unstructured":"Essink, B. et al. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Lancet. Infect. Dis. 23, 621\u2013633 (2023).","journal-title":"Lancet. Infect. Dis."},{"key":"7661_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/infdis\/jix592","volume":"217","author":"M Meyer","year":"2017","unstructured":"Meyer, M. et al. Modified mRNA-Based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J. Infect. Dis. 217, 451\u2013455 (2017).","journal-title":"J. Infect. Dis."},{"key":"7661_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.puhe.2021.02.025","volume":"194","author":"G Troiano","year":"2021","unstructured":"Troiano, G. & Nardi, A. Vaccine hesitancy in the era of COVID-19. Public Health 194, 245\u2013251. https:\/\/doi.org\/10.1016\/j.puhe.2021.02.025 (2021).","journal-title":"Public Health"},{"key":"7661_CR18","doi-asserted-by":"crossref","unstructured":"Sadoff, J., et al. Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine. N. Engl. J. Med. 384, 1824\u20131835 (2021).","DOI":"10.1056\/NEJMoa2034201"},{"key":"7661_CR19","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/vaccines9090974","volume":"9","author":"XR Lim","year":"2021","unstructured":"Lim, X. R. et al. Pseudo-Anaphylactic reactions to Pfizer BNT162B2 vaccine: Report of 3 cases of anaphylaxis post Pfizer BNT162B2 vaccination. Vaccines. 9, 974 (2021).","journal-title":"Vaccines."},{"key":"7661_CR20","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1002\/iid3.807","volume":"11","author":"F Yasmin","year":"2023","unstructured":"Yasmin, F. et al. Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun. Inflamm. Dis. 11, e807. https:\/\/doi.org\/10.1002\/iid3.807 (2023).","journal-title":"Immun. Inflamm. Dis."},{"key":"7661_CR21","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.tru.2022.100104","volume":"7","author":"Z Yousaf","year":"2022","unstructured":"Yousaf, Z., Ata, F. & Hammamy, R. Thrombosis post-mRNA-based SARS-CoV-2 vaccination (BNT162b2)\u2014time to think beyond thrombosis with thrombocytopenia syndrome (TTS). Thrombos. Update. 7, 100104 (2022).","journal-title":"Thrombos. Update."},{"key":"7661_CR22","unstructured":"WHO. Guidelines on the non-clinical evaluation of vaccine adjuvants and adjuvanted vaccines, Annex 2, TRS No 987 (2013). https:\/\/www.who.int\/publications\/m\/item\/nonclinical-evaluation-of-vaccine-adjuvants-and-adjuvanted-vaccines-annex-2-trs-no-987."},{"key":"7661_CR23","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1016\/j.jaip.2021.03.055","volume":"9","author":"CL Ramos","year":"2021","unstructured":"Ramos, C. L. & Kelso, J. M. \u201cCOVID Arm\u201d: Very delayed large injection site reactions to mRNA COVID-19 vaccines. J. Allergy. Clin. Immunol. Prac. 9, 2480\u20132481 (2021).","journal-title":"J. Allergy. Clin. Immunol. Prac."},{"key":"7661_CR24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/jat.3314","volume":"36","author":"P Baldrick","year":"2016","unstructured":"Baldrick, P. Dose site reactions and related findings after vaccine administration in safety studies. J. Appl. Toxicol. 36, 980\u2013990 (2016).","journal-title":"J. Appl. Toxicol."},{"key":"7661_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9, C., Laup\u00e8ze, B., Del Giudice, G., Didierlaurent, A. M. & Da Silva, F. T. The how\u2019s and what\u2019s of vaccine reactogenicity. NPJ. Vaccines. 4, 38 (2019).","journal-title":"NPJ. Vaccines."},{"key":"7661_CR26","doi-asserted-by":"publisher","first-page":"7226","DOI":"10.1038\/s41467-024-51411-9","volume":"15","author":"Kim","year":"2024","unstructured":"Kim, et al. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site. Nat. Commun. 15, 7226 (2024).","journal-title":"Nat. Commun."},{"key":"7661_CR27","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 24, 103479. https:\/\/doi.org\/10.1016\/j.isci.2021.103479 (2021).","journal-title":"iScience."},{"key":"7661_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","volume":"10","author":"AE Zelkoski","year":"2025","unstructured":"Zelkoski, A. E. et al. Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4. NPJ. Vacc. 10, 73. https:\/\/doi.org\/10.1038\/s41541-025-01124-x (2025).","journal-title":"NPJ. Vacc."},{"key":"7661_CR29","doi-asserted-by":"publisher","first-page":"e2005191118","DOI":"10.1073\/pnas.2005191118","volume":"118","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc. Natl. Acad. Sci. 118, e2005191118. https:\/\/doi.org\/10.1073\/pnas.2005191118 (2021).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"7661_CR30","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/jdv.17806","volume":"36","author":"E Cinotti","year":"2021","unstructured":"Cinotti, E. et al. Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination. J. Eur. Acad. Dermatol. Venereol. 36, e171\u2013e172. https:\/\/doi.org\/10.1111\/jdv.17806 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"7661_CR31","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/jdv.17685","volume":"36","author":"L De Montjoye","year":"2021","unstructured":"De Montjoye, L., Marot, L. & Baeck, M. Eosinophilic cellulitis after BNT162b2 mRNA Covid-19 vaccine. J. Eur. Acad. Dermatol. 36, e26\u2013e28. https:\/\/doi.org\/10.1111\/jdv.17685 (2021).","journal-title":"J. Eur. Acad. Dermatol."},{"key":"7661_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1086\/422454","volume":"39","author":"KS Kohl","year":"2004","unstructured":"Kohl, K. S. et al. Fever after immunization: current concepts and improved future scientific understanding. Clin. Infect. Dis. 39, 389\u2013394 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"7661_CR33","unstructured":"ICH guidline. Safety pharmacology studies for human pharmaceuticalsS7A (2001). https:\/\/www.ich.org\/page\/safety-guidelines."},{"key":"7661_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/rth2.12252","volume":"3","author":"ACN Barbosa","year":"2019","unstructured":"Barbosa, A. C. N. et al. Prolonged APTT of unknown etiology: a systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit. Res. Prac. Thromb. Haemost. 3, 749\u2013757 (2019).","journal-title":"Res. Prac. Thromb. Haemost."},{"key":"7661_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ddr.430320408","volume":"32","author":"DJ Murphy","year":"1994","unstructured":"Murphy, D. J. Safety pharmacology of the respiratory system: Techniques and study design. Drug. Dev. Res. 32, 237\u2013246 (1994).","journal-title":"Drug. Dev. Res."},{"key":"7661_CR36","doi-asserted-by":"publisher","first-page":"106700","DOI":"10.1016\/j.cct.2022.106700","volume":"115","author":"A Jensen","year":"2022","unstructured":"Jensen, A. et al. COVID-19 vaccines: considering sex differences in efficacy and safety. Contemp. Clin. Trials. 115, 106700 (2022).","journal-title":"Contemp. Clin. Trials."},{"key":"7661_CR37","unstructured":"National Research Council (US) Committee. GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS (2011). https:\/\/grants.nih.gov\/grants\/olaw\/guide-for-the-care-and-use-of-laboratory-animals.pdf."},{"key":"7661_CR38","unstructured":"MFDS (Republic of Korea). Ministry of Food and Drug Safety notification no. 2022- 93. Good Laboratory Practice Regulations for Nonclinical Laboratory Studies (2023). https:\/\/www.law.go.kr\/admRulLsInfoP.do?admRulSeq=2100000217622."},{"key":"7661_CR39","unstructured":"OECD. OECD Principles on Good Laboratory Practice. ENV\/MC\/CHEM (98)17 (1997). https:\/\/read.oecd-ilibrary.org\/environment\/oecd-principles-on-good-laboratory-practice_9789264078536-en#page1."},{"key":"7661_CR40","unstructured":"MFDS (Republic of Korea). Standard for Toxicity Study of Pharmaceuticals: annex 1 single dose toxicity study and annex 2 repeated dose toxicity study (2022). https:\/\/www.law.go.kr\/LSW\/admRulLsInfoP.do?chrClsCd=&admRulSeq=2100000209652."},{"key":"7661_CR41","unstructured":"ICH guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (Qt Interval Prolongation) by human pharmaceuticals, S7B (2005). https:\/\/www.ich.org\/page\/safety-guidelines."},{"key":"7661_CR42","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nat. 602, 657\u2013663 (2022).","journal-title":"Nat."},{"key":"7661_CR43","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","volume":"602","author":"E Cameroni","year":"2022","unstructured":"Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nat. 602, 664\u2013670 (2022).","journal-title":"Nat."},{"key":"7661_CR44","doi-asserted-by":"crossref","unstructured":"Wang, Q., Guo, Y., Iketani, S., et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nat. 608, 603\u2013608 (2022).","DOI":"10.1038\/s41586-022-05053-w"},{"key":"7661_CR45","doi-asserted-by":"crossref","unstructured":"Qu, P., Faraone, J., Evans, J. P., et al. Neutralization of the SARS-CoV-2 Omicron BA.4\/5 and BA.2.12.1 subvariants. N. Engl. J. Med. 386, 474\u2013476 (2022).","DOI":"10.1056\/NEJMc2206725"},{"key":"7661_CR46","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1038\/s41467-021-25479-6","volume":"12","author":"TA Bates","year":"2021","unstructured":"Bates, T. A. et al. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nat. Commun. 12, 5135 (2021).","journal-title":"Nat. Commun."},{"key":"7661_CR47","doi-asserted-by":"publisher","first-page":"e2161422","DOI":"10.1080\/22221751.2022.2161422","volume":"12","author":"J Xia","year":"2023","unstructured":"Xia, J. et al. Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages. Emerg. Microbes. Infect. 12, e2161422. https:\/\/doi.org\/10.1080\/22221751.2022.2161422 (2023).","journal-title":"Emerg. Microbes. Infect."},{"key":"7661_CR48","doi-asserted-by":"publisher","unstructured":"Imbiakha, F. et al. Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5. Sci. Adv. 9, eadj1736. https:\/\/doi.org\/10.1126\/sciadv.adj1736 (2023).","DOI":"10.1126\/sciadv.adj1736"},{"key":"7661_CR49","doi-asserted-by":"publisher","first-page":"117783","DOI":"10.1016\/j.jep.2024.117783","volume":"325","author":"SE Min","year":"2024","unstructured":"Min, S. E. et al. Evaluating the toxicity of the roots of Asarum heterotropoides var. mandshuricum extracted using the decoction method: genotoxicity, single-dose toxicity, and 13-week repeated-dose toxicity studies. J. Ethnopharmacol. 325, 117783 (2024).","journal-title":"J. Ethnopharmacol."},{"key":"7661_CR50","unstructured":"FDA. Guidance on S7A Safety Pharmacology Studies for Human Pharmaceuticals. Fed. Regist. 66, 36791\u201336792 (2001). https:\/\/www.federalregister.gov\/documents\/2001\/07\/13\/01-17498\/international-conference-on-harmonisation-guidance-on-s7a-safety-pharmacology-studies-for-human."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07661-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07661-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07661-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:06:28Z","timestamp":1751396788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07661-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7661"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07661-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal. The study design was approved by the appropriate ethics review board. We have read and understood your journal\u2019s policies, and we believe that neither the manuscript nor the study violates any of these. Woo Ghil Lee, Seong In Jeong, and Ji Young Song are employees of Rnagene, Inc. The other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21831"}}